Inventiva S.A. (NYSE:IVA)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $14.64, but opened at $15.10. Inventiva shares last traded at $15.10, with a volume of 220 shares changing hands.
A number of research analysts recently issued reports on the company. Societe Generale reaffirmed a “sell” rating on shares of Inventiva in a report on Monday, March 15th. Roth Capital restated a “buy” rating on shares of Inventiva in a research report on Tuesday, May 4th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Inventiva currently has an average rating of “Buy” and an average price target of $27.33.
The stock’s 50-day simple moving average is $14.10.
About Inventiva (NYSE:IVA)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH.
Read More: Shanghai Stock Exchange Composite Index
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.